{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:28:26Z","timestamp":1740547706696,"version":"3.38.0"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Patients who suffer from motion sickness despite avoiding triggers and using behavioral modifications may benefit from individualized recommendations for pharmacologic therapy. Patients with refractory motion sickness can benefit from prophylactic drug therapy using first-generation antihistamines or scopolamine.<\/jats:p>","DOI":"10.1097\/01.jaa.0000000000000097","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T15:04:46Z","timestamp":1740495886000},"page":"16-18","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Choosing a drug to treat motion sickness"],"prefix":"10.1097","volume":"38","author":[{"given":"Gayle B.","family":"Bodner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney J.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"1","key":"R1-20250225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WCO.0000000000001018","article-title":"Motion sickness: current concepts and management","volume":"35","author":"Keshavarz","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"R2-20250225","first-page":"41","article-title":"Prevention and treatment of motion sickness","volume":"90","author":"Brainard","year":"2014","journal-title":"Am Fam Physician"},{"key":"R3-20250225","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2019-9-4","article-title":"Motion sickness: an overview","volume":"8","author":"Leung","year":"2019","journal-title":"Drugs Context"},{"issue":"11","key":"R5-20250225","first-page":"1111","article-title":"The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness","volume":"71","author":"Levine","year":"2000","journal-title":"Aviat Space Environ Med"},{"issue":"6","key":"R6-20250225","first-page":"CD002851","article-title":"Scopolamine (hyoscine) for preventing and treating motion sickness","volume":"2011","author":"Spinks","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"R7-20250225","first-page":"CD012715","article-title":"Antihistamines for motion sickness","volume":"10","author":"Karrim","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"R8-20250225","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/106002800303700201","article-title":"Failure of cetirizine and fexofenadine to prevent motion sickness","volume":"37","author":"Cheung","year":"2003","journal-title":"Ann Pharmacother"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000000000000097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T15:04:49Z","timestamp":1740495889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000000000000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000000000000097","relation":{},"ISSN":["1547-1896","0893-7400"],"issn-type":[{"value":"1547-1896","type":"print"},{"value":"0893-7400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}